PLCL2

PLCL2 is a catalytically inactive phospholipase C-like protein that functions as a signaling modulator in immune, endocrine, and metabolic contexts. Its PH domain binds PI(4,5)P2 and Ins(1,4,5)P3 and targets the protein to perinuclear/endoplasmic reticulum membranes, but substitution of two essential catalytic residues (His→Thr, Tyr→Phe) abolishes PLC enzymatic activity (PMID:10581172). In B lymphocytes, PLCL2 negatively regulates BCR signaling by suppressing calcium influx, NFATc nuclear accumulation, and ERK activation, thereby restraining mature B cell proliferation and T-cell-independent antigen responses (PMID:14517301). In the uterus, PLCL2 is a transcriptional target of progesterone receptor isoform B—driven via a PGR-occupied upstream enhancer—and attenuates myometrial contractility through the Oxtr–PLCL2–Trpc3 axis, while in adipocytes it interacts with the insulin receptor to maintain its surface retention and support downstream Akt signaling (PMID:33707208, PMID:40493036, PMID:34859819).

1. 1999 High

   Establishing that PLCL2 is a PLC-family member that retains phosphoinositide binding but lacks catalytic activity resolved the question of whether all PLC-like proteins are enzymes, and identified PI(4,5)P2/IP3 binding and perinuclear/ER localization as defining features.

   Evidence Site-directed mutagenesis of catalytic residues, lipid-binding assays, and GFP-fusion localization in C2C12 and COS7 cells

   PMID:10581172

   Open questions at the time

   • No physiological function or signaling pathway had yet been assigned
   • Mechanism by which PI(4,5)P2 binding without catalysis affects signaling was unknown
2. 2003 High

   Genetic deletion of PLCL2 in mice revealed it as a negative regulator of BCR signaling—suppressing Ca²⁺ flux, NFATc activation, and ERK activity—thereby defining its first physiological role as a brake on B cell activation.

   Evidence PLCL2 knockout mouse with calcium flux, NFATc localization, ERK activity, proliferation, and antigen response assays

   PMID:14517301

   Open questions at the time

   • Molecular mechanism by which catalytically dead PLCL2 dampens Ca²⁺ signaling (e.g., PI(4,5)P2 sequestration vs. adaptor function) was not resolved
   • Whether PLCL2 acts cell-autonomously in B cells was not formally shown
3. 2009 Medium

   PLCL1/PLCL2 double-knockout mice exhibited elevated gonadotropin secretion and impaired female reproduction, extending the functional scope of PLCL2 to neuroendocrine regulation, though individual contributions of the two paralogs remained unresolved.

   Evidence PLCL1/PLCL2 double-knockout mice; serum LH/FSH measurements; pituitary explant cultures; estrous cycle monitoring

   PMID:19553601

   Open questions at the time

   • PLCL2-specific contribution was not genetically separated from PLCL1
   • Molecular targets of PLCL2 in pituitary gonadotrophs were not identified
4. 2021 High

   Identification of PLCL2 as a downstream effector of progesterone receptor isoform B in the uterus established a new tissue context and placed PLCL2 within the Oxtr–PLCL2–Trpc3 pathway controlling myometrial contractility.

   Evidence Transgenic PGR-A/PGR-B mouse models; uterine RNA-seq; ex vivo and in vivo contractility assays; CRISPRa gain-of-function

   PMID:33707208

   Open questions at the time

   • Direct biochemical interaction between PLCL2 and Oxtr or Trpc3 was not demonstrated
   • Whether PLCL2 acts by sequestering phosphoinositides or via protein–protein interactions in myometrium was unclear
5. 2022 Medium

   Demonstration that PLCL2 (together with PLCL1) interacts with the insulin receptor and promotes its surface retention and downstream Akt signaling in adipocytes revealed a metabolic function involving receptor trafficking regulation.

   Evidence PLCL1/PLCL2 double-knockout mouse adipocytes; co-immunoprecipitation with IR; glucose uptake assay; Rab5 siRNA rescue of surface IR

   PMID:34859819

   Open questions at the time

   • PLCL2-specific contribution was not genetically separated from PLCL1
   • Whether PLCL2 binds the IR directly or through an adaptor complex is unresolved
   • Structural basis of PLCL2–IR interaction is unknown
6. 2025 Medium

   Identification of a PGR-occupied enhancer 35 kb upstream of PLCL2 that drives its transcription in myometrial cells provided the cis-regulatory mechanism linking progesterone signaling to PLCL2 expression.

   Evidence H3K27ac/H3K4me1 ChIP-seq, chromatin conformation capture, PGR overexpression, CRISPRa activation of enhancer in human myometrial cells

   PMID:40493036

   Open questions at the time

   • Whether this enhancer operates in other PGR-expressing tissues is unknown
   • In vivo validation of enhancer necessity (e.g., enhancer deletion mouse) is lacking

• The unifying molecular mechanism by which a catalytically dead PLC-like protein modulates diverse signaling pathways—whether through phosphoinositide sequestration, scaffolding, or competition with active PLCs—remains unresolved.
• No structural model of full-length PLCL2 exists
• Relative importance of PI(4,5)P2 binding versus protein–protein interactions for each tissue function is unknown
• PLCL2-specific versus PLCL1-redundant functions have not been genetically separated in endocrine and metabolic tissues